Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
Aaron R. Hansen(Princess Margaret Cancer Centre), Christophe Massard(Institut Gustave Roussy), Patrick A. Ott(Dana-Farber Cancer Institute), Naomi B. Haas(Hospital of the University of Pennsylvania), Juanita Lopez(Institute of Cancer Research), Samuel Ejadi(HonorHealth), John M. Wallmark(Hematology Oncology Associates), Bhumsuk Keam(Seoul National University Hospital), Jean‐Pierre Delord(Institut Claudius Regaud), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), M. Gould(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peng Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen J. O’Keefe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center)
Cited by 367
Abstract
Related Papers
No related papers found
Powered by citation graph analysis